FrancophonIA/ELRC3.0 huggingface dataset:
English: A similar increase in exposure was observed when ticagrelor was administered immediately prior to dialysis (49% and 61%, respectively) showing that ticagrelor is not dialysable.
Croatian: Slično povećanje izloženosti opaženo je kada se tikagrelor primijenio neposredno prije dijalize (49% i 61%), što pokazuje da se tikagrelor ne može dijalizirati.
English: • Severe pain and swelling in your joints - these are signs of gout
Croatian: • Jaka bol i oticanje Vaših zglobova - ovo su znakovi gihta
English: Brilique is not likely to affect your ability to drive or use machines.
Croatian: Nije vjerojatno da Brilique utječe na Vašu sposobnost upravljanja vozilima ili strojevima.
English: • You can take the tablet with or without food.
Croatian: • Tabletu možete uzimati s hranom ili bez nje.
English: A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ticagrelor therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Croatian: Potrebno je odlučiti da li prekinuti dojenje ili prekinuti liječenje/suzdržati se od liječenja tikagrelorom uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
English: The mechanism has not been elucidated.
Croatian: Mehanizam nije razjašnjen.
English: • A 2-fold increase of ticagrelor exposure was observed after daily consumption of large quantities of grapefruit juice (3x200 ml).
Croatian: • Primijećeno je dvostruko povećanje izloženosti tikagreloru nakon dnevnog unosa velikih količina soka od grejpa (3x200 ml).
English: Ticagrelor also increases local endogenous adenosine levels by inhibiting the equilibrative nucleoside transporter-1 (ENT-1).
Croatian: Tikagrelor također podiže lokalne endogene razine adenozina inhibicijom uravnotežujućeg transportera nukleozida-1 (ENT-1).
English: Clinical efficacy and safety The clinical evidence for the efficacy and safety of ticagrelor is derived from two phase 3 trials:
Croatian: Klinička djelotvornost i sigurnost Klinički dokazi o djelotvornosti i sigurnosti tikagrelora dobiveni su iz dva klinička ispitivanja faze 3:
English: • Crush the tablet to a fine powder.
Croatian: • Zdrobite tabletu u fini prašak
English: KM% p-value
Croatian: KM% p-vrijednost
English: This reduces the chance of a blood clot forming that can reduce blood flow.
Croatian: Ovo smanjuje mogućnost stvaranja krvnog ugruška koji može smanjiti protok krvi.
English: Taking Brilique with other medicines for blood clotting Your doctor will usually also tell you to take acetylsalicylic acid.
Croatian: Uzimanje lijeka Brilique s drugim lijekovima koji sprječavaju zgrušavanje krvi Liječnik će Vam obično reći da uzimate i acetilsalicilatnu kiselinu.
English: • ‘oral anticoagulants' often referred to as ‘blood thinners' which include warfarin.
Croatian: • „oralni antikoagulansi“, često se nazivaju lijekovima „za razrjeđivanje krvi“, što uključuje varfarin.
English: The orodispersible tablets may be used as an alternative to Brilique 90 mg film-coated tablets for patients who have difficulty swallowing the tablets whole or for whom there is a preference for orodispersible tablets.
Croatian: Raspadljive tablete za usta mogu se koristiti kao alternativa Brilique 90 mg filmom obloženim tabletama kod bolesnika koji imaju poteškoća s gutanjem cijelih tableta ili kod onih koji preferiraju raspadljive tablete za usta.
English: Similar increases in AUC and Cmax were observed for all atorvastatin acid metabolites.
Croatian: Slična su povećanja AUC-a i Cmax uočena za sve metabolite atorvastatinske kiseline.
English: • Blood in your ear
Croatian: • Krv u uhu
English: If you take more Brilique than you should
Croatian: Ako uzmete više lijeka Brilique nego što ste trebali
English: Combined efficacy and safety composite
Croatian: Kombinacija djelotvornosti i sigurnosti primjene
English: If a patient reports new, prolonged or worsened dyspnoea this should be investigated fully and if not tolerated, treatment with ticagrelor should be stopped.
Croatian: Ako bolesnik prijavi novu, produljenu ili pogoršanu dispneju, to treba u potpunosti istražiti i ako ju ne podnosi, liječenje tikagrelorom treba prekinuti.
English: Brilique can be administered with or without food.
Croatian: Brilique se može uzimati s hranom ili bez nje.
English: In particular, tell your doctor or pharmacist if you are taking any of the following medicines that increase your risk of bleeding:
Croatian: Svakako kažite svom liječniku ili ljekarniku ako uzimate bilo koji od sljedećih lijekova koji povećavaju rizik od krvarenja:
English: • Allergic reaction - a rash, itching or a swollen face or swollen lips/tongue may be signs of an allergic reaction
Croatian: • Alergijske reakcije - osip, svrbež, oticanje lica ili oticanje usana/jezika mogu biti znakovi alergijske reakcije
English: Also tell your doctor that because you are taking Brilique, you may have an increased risk of bleeding if your doctor gives you fibrinolytics, often called ‘clot dissolvers', such as streptokinase or alteplase.
Croatian: Također kažite svom liječniku da ste zbog uzimanja Briliquea izloženi većem riziku od krvarenja, ako Vam liječnik propiše fibrinolitike, koji se često nazivaju lijekovima „koji otapaju ugruške“ kao što su streptokinaza ili alteplaza.
English: • morphine and other opioids (used to treat severe pain)
Croatian: • morfin i drugi opioidi (za liječenje teške boli).
English: The exposure in patients self-identified as Hispanic or Latino was similar to that in Caucasians.
Croatian: Izloženost u bolesnika koji se smatraju hispanskog ili latino podrijetla bila je slična onoj u bijelaca.
English: This suggests it is appropriate to treat patients with ticagrelor 90 mg twice daily for 12 months (see section 4.2).
Croatian: Ovo ukazuje da je prikladno liječiti bolesnike tikagrelorom u dozi od 90 mg dvaput dnevno tijekom 12 mjeseci (vidjeti dio 4.2).
English: Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Croatian: Obavijestite liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: When radiolabelled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (57.8% in faeces, 26.5% in urine).
Croatian: Kada se daje radioobilježeni tikagrelor, prosječna vrijednost izlučene radioaktivnosti je približno 84% (57,8% u fecesu i 26,5% u urinu).
English: SRI = serious recurrent ischaemia; RI = recurrent ischaemia; TIA = transient ischaemic attack; ATE = arterial thrombotic event.
Croatian: SRI = ozbiljna ponovljena ishemija; RI = ponovljena ishemija; TIA = tranzitorna ishemijska ataka; ATE = arterijski trombotični događaj.
English: Figure 1 shows the estimate of the risk to the first occurrence of any event in the composite efficacy endpoint.
Croatian: Slika 1 prikazuje procjenu rizika za prvo pojavljivanje bilo kojeg događaja složene mjere ishoda djelotvornosti.
English: ARR (%/yr)
Croatian: ARR (%/god)
English: What Brilique is
Croatian: Što je Brilique
English: Pharmacotherapeutic group: Platelet aggregation inhibitors excluding heparin, ATC code: B01AC24
Croatian: Farmakoterapijska skupina: Inhibitori agregacije trombocita isključujući heparin, ATK oznaka: B01AC24
English: The incidence of intracranial bleeding was low in both treatment groups given the significant comorbidity and CV risk factors of the population under study.
Croatian: Incidencija intrakranijalnih krvarenja bila je niska u obje terapijske skupine, uzevši u obzir značajne komorbiditete i kardiovaskularne rizične faktore ispitivane populacije.
English: Patients received a 300 mg loading dose of clopidogrel (600 mg possible if having PCI) or 180 mg of ticagrelor.
Croatian: Bolesnici su primili 300 mg udarne doze klopidogrela (moguće i 600 mg ako su imali PCI) ili 180 mg tikagrelora.
English: • the clot can partly block the blood vessels to the heart; this reduces the blood flow to the heart and can cause chest pain which comes and goes (called ‘unstable angina').
Croatian: • ugrušak može djelomično blokirati krvne žile do srca; što smanjuje protok krvi prema srcu i može izazvati prolaznu bol u prsnom košu (koja se naziva „nestabilna angina“).
English: PLATO Major or Minor
Croatian: PLATO velika ili manja
English: Fatal/Life-threatening
Croatian: Fatalna/opasna po život
English: If you stop taking Brilique
Croatian: Ako prestanete uzimati Brilique
English: If clinically indicated, ticagrelor should be used with caution in the following patient groups:
Croatian: Ako postoje kliničke indikacije, tikagrelor treba koristiti s oprezom u sljedećim skupinama bolesnika:
English: Acute coronary syndromes
Croatian: Akutni koronarni sindromi
English: Each of the components contributed to the reduction in the primary composite endpoint (CV death 17% RRR, MI 16% RRR and stroke 25% RRR).
Croatian: Svaka od komponenti doprinijela je smanjenju primarnog kompozitnog ishoda (KV smrt 17% RRR, IM 16% RRR i moždani udar 25% RRR).
English: If you have trouble swallowing the tablet If you have trouble swallowing the tablet you can crush it and mix with water as follows:
Croatian: Ukoliko imate problema sa gutanjem tablete možete je zdrobiti i pomiješati sa vodom na sljedeći način:
English: The primary route of ticagrelor elimination is via hepatic metabolism.
Croatian: Primarni put eliminacije tikagrelora je putem jetrenog metabolizma.
English: Brilique-related breathlessness is generally mild and characterised as a sudden, unexpected hunger for air usually occurring at rest and may appear in the first weeks of therapy and for many may disappear.
Croatian: Nedostatak zraka povezan s lijekom Brilique općenito je blaga nuspojava za koju je karakteristična iznenadna, neočekivana glad za zrakom, koja se obično javlja u mirovanju i može se javiti u prvim tjednima liječenja te nestati nakon dužeg vremena.
English: Your doctor will discuss with you the benefits and risks of taking Brilique during this time.
Croatian: Vaš liječnik će Vam objasniti koristi i rizike od uzimanja lijeka Brilique tijekom razdoblja dojenja.
English: Therefore, premature discontinuation of treatment should be avoided.
Croatian: Stoga treba izbjegavati prijevremeni prekid terapije.
English: • To take out the tablet, tear open the blister foil - do not push it through the foil because the tablet may break.
Croatian: • Kako bi izvadili tabletu, odvojite foliju blistera - nemojte gurati tabletu kroz blister jer se tableta može razlomiti.
English: Treatment can also be initiated up to 2 years from the MI, or within one year after stopping previous ADP receptor inhibitor treatment.
Croatian: Liječenje se također može započeti do 2 godine nakon infarkta miokarda, ili unutar jedne godine nakon prekida prethodnog liječenja inhibitorom ADP receptora.
English: • Feeling dizzy or like the room is spinning
Croatian: • Osjećaj omaglice ili osjećaj da se soba okreće
English: The mean absolute bioavailability of ticagrelor was estimated to be 36%.
Croatian: Srednja apsolutna bioraspoloživost tikagrelora procijenjena je na 36%.
English: Ticagrelor does not affect tests of pulmonary function.
Croatian: Tikagrelor ne utječe na testove plućne funkcije.
English: • Patients with a propensity to bleed (e.g. due to recent trauma, recent surgery, coagulation disorders, active or recent gastrointestinal bleeding).
Croatian: • Bolesnici sa sklonošću krvarenjima (npr. uslijed nedavne traume, operacije, poremećaja koagulacije, aktivnog ili nedavnog gastrointestinalnog krvarenja).
English: Dyspnoea is usually mild to moderate in intensity and often resolves without need for treatment discontinuation.
Croatian: Dispneja je obično blagog do umjerenog intenziteta i često nestaje bez potrebe za prestankom liječenja.
English: In patients with ACS, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.
Croatian: U bolesnika sa ACS-om kod kojih se morfin ne može prekinuti i u kojih se brzi inhibitori P2Y12 receptora smatraju neophodnim, može se razmotriti uporaba parenteralnih inhibitora P2Y12 receptora.
English: Initial exposure (0.5 and 1 hour post-dose) from crushed ticagrelor tablets mixed in water was higher compared to whole tablets, with a generally identical concentration profile thereafter (2 to 48 hours).
Croatian: Početna izloženost (0,5 i 1 sat nakon primjene doze) smrvljenih tikagrelor tableta promiješanih u vodi bila je viša u usporedbi sa cijelim tabletama, s općenito identičnim profilom koncentracije nakon toga (2 do 48 sati).
English: Brilique helps stop the clumping of platelets.
Croatian: Brilique pomaže u sprječavanju nakupljanja krvnih pločica.
English: • beta blockers and verapamil (used to treat high blood pressure)
Croatian: • beta blokatore i verapamil (za liječenje visokog krvnog tlaka),
English: During treatment with ticagrelor, dizziness and confusion have been reported.
Croatian: Tijekom liječenja tikagrelorom prijavljene su omaglica i konfuzija.
English: Studies in rats and rabbits have shown reproductive toxicity, with slightly reduced maternal body weight gain and reduced neonatal viability and birth weight, with delayed growth.
Croatian: Ispitivanja na štakorima i zečevima su pokazala reproduktivnu toksičnost, s blagim smanjenjem dobivanja na tjelesnoj težini majke i smanjenom neonatalnom vitalnošću i porođajnom težinom, i s odgođenim razvojem.
English: Some bleeding is common (like bruising and nosebleeds).
Croatian: Neka krvarenja su česta (poput stvaranja modrica ili krvarenja iz nosa).
English: The RRR for the composite endpoint from 1 to 360 days (17% RRR) and from 361 days and onwards (16% RRR) was similar.
Croatian: RRR za kompozitni krajnji ishod od 1. do 360. dana (17% RRR) te od 361. dana nadalje (16% RRR) bio je sličan.
English: There were no adverse clinical consequences associated with this imbalance (including pacemaker insertions) in this population of patients.
Croatian: Nije bilo neželjenih kliničkih posljedica povezanih s ovom neravnotežom (uključujući ugradnju elektrostimulatora) u ovoj populaciji bolesnika.
English: A negative RRR indicates a relative risk increase.
Croatian: Negativni RRR ukazuje na povećanje relativnog rizika. isključuje tihi IM.
English: Gastrointestinal irritation was observed in several animal species at clinical relevant exposure levels (see section 4.8).
Croatian: Gastrointestinalna iritacija je primijećena kod nekoliko životinjskih vrsta pri klinički značajnim razinama izloženosti (vidjeti dio 4.8).
English: Other TIMI Major
Croatian: Ostala TIMI velika
English: If a patient is to undergo elective surgery and antiplatelet effect is not desired, ticagrelor should be discontinued 5 days prior to surgery (see section 5.1).
Croatian: Ako bolesnika treba podvrgnuti elektivnom kirurškom zahvatu i antiagregacijski učinak nije poželjan, tikagrelor treba prestati primjenjivati 5 dana prije operacije (vidjeti dio 5.1).
English: • Visual problems caused by blood in your eye
Croatian: • Smetnje vida uzrokovane krvi u Vašem oku
English: Preclinical data for ticagrelor and its major metabolite have not demonstrated unacceptable risk for adverse effects for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxic potential.
Croatian: Neklinički podaci o tikagreloru i njegovom glavnom metabolitu ne ukazuju na neprihvatljiv rizik od nuspojava za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti jednokratne i ponovljenih doza i ispitivanja genotoksičnog potencijala.
English: Absorption of ticagrelor is rapid with a median tmax of approximately 1.5 hours.
Croatian: Apsorpcija tikagrelora je brza, s medijanom tmax od približno 1,5 sati.
English: *p-value calculated from Cox proportional hazards model with treatment group as the only explanatory variable.
Croatian: *p-vrijednost izračunata iz Coxovog modela proporcionalnih hazarda s terapijskom skupinom kao jedinom eksplanatornom varijablom
English: There are limited data on the efficacy and safety of ticagrelor beyond 3 years of extended treatment.
Croatian: Postoje ograničeni podaci o djelotvornosti i sigurnosti tikagrelora nakon 3 godine produženog liječenja.
English: p-value*
Croatian: p-vrijednost*
English: Ticagrelor is not recommended during pregnancy.
Croatian: Ne preporučuje se koristiti tikagrelor tijekom trudnoće.
English: Similarly, when removing all procedure related bleeds, more bleeding occurred with ticagrelor than with clopidogrel (Table 2).
Croatian: Slično tome, kad se otklone sva krvarenje povezana s postupcima, više krvarenja se dogodilo s tikagrelorom nego s klopidogrelom (tablica 2).
English: Recoveries of ticagrelor and the active metabolite in urine were both less than 1% of the dose.
Croatian: Količina izlučenog tikagrelora i aktivnog metabolita u urinu je za obje tvari manja od 1% doze.
English: PERFORATED UNIT DOSE BLISTER
Croatian: PERFORIRANI BLISTER S JEDINIČNIM DOZAMA
English: It might be due to your heart disease or another cause, or it might be a side effect of Brilique.
Croatian: Vaša srčana bolest ili drugi uzrok, ili može biti nuspojava lijeka Brilique.
English: However, platelets can also form clots inside diseased blood vessels in the heart and brain.
Croatian: Međutim, krvne pločice također mogu stvoriti krvne ugruške u oboljelim krvnim žilama srca ili mozga.
English: • Bleeding caused by blood disorders
Croatian: • Krvarenje uzrokovano poremećajima krvi
English: Take this medicine on a regular basis and for as long as your doctor keeps prescribing it.
Croatian: Uzimajte ovaj lijek redovito i onoliko dugo koliko Vam ga liječnik propisuje.
English: Ticagrelor demonstrates linear pharmacokinetics and exposure to ticagrelor and the active metabolite (AR-C124910XX) are approximately dose proportional up to 1260 mg.
Croatian: Tikagrelor pokazuje linearnu farmakokinetiku, a izloženost tikagreloru i aktivnom metabolitu (AR-C124910XX) je približno proporcionalna dozi do 1260 mg.
English: Brilique treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily.
Croatian: Liječenje lijekom Brilique treba početi s jednokratnom udarnom dozom od 180 mg (dvije tablete od 90 mg), a zatim nastaviti s 90 mg dvaput na dan.
English: The clinical relevance is unknown, but data indicate the potential for reduced ticagrelor efficacy in patients co-administered ticagrelor and morphine.
Croatian: Klinički značaj je nepoznat, ali podaci pokazuju potencijal smanjenja djelotvornosti tikagrelora u bolesnika koji su istodobno uzimali tikagrelor i morfin.
English: The majority of these bleedings were of less severity (classified as TIMI Requiring medical attention), e.g. epistaxis, bruising and haematomas.
Croatian: Većina ovih krvarenja bila je blaža (klasificirana kao TIMI koja zahtijevaju medicinsku pozornost), npr. epistaksa, stvaranje modrica i hematom.
English: Medicinal products metabolised by CYP2C9
Croatian: Lijekovi koje metabolizira CYP2C9
English: Most reported symptoms of dyspnoea were mild to moderate in intensity, and most were reported as a single episode early after starting treatment.
Croatian: Većina prijavljenih simptoma dispneje bila je blage do umjerene jačine i većina je prijavljena kao jedna epizoda rano nakon početka liječenja.
English: Table 5 - Analysis of primary and secondary efficacy endpoints (PEGASUS)
Croatian: Tablica 5 - Analiza primarnih i sekundarnih ishoda djelotvornosti (PEGASUS)
English: A delayed and decreased exposure to oral P2Y12 inhibitors, including ticagrelor and its active metabolite, has been observed in patients with ACS treated with morphine (35% reduction in ticagrelor exposure).
Croatian: Odgođena i smanjena izloženost oralnim inhibitorima P2Y12 receptora, uključujući tikagrelor i njegove aktivne metabolite, zapažena je u bolesnika sa ACS-om liječenih sa morfinom (35% smanjenje izloženosti tikagreloru).
English: Antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and/or recombinant factor VIIa therapy may increase haemostasis.
Croatian: Antifibrinolitička terapija (aminokaproična i traneksamična kiselina) i/ili terapija rekombinantnim faktorom VIIa mogu povećati hemostazu.
English: Women of childbearing potential should use appropriate contraceptive measures to avoid pregnancy during ticagrelor therapy.
Croatian: Žene reproduktivne dobi bi trebale koristiti odgovarajuće kontracepcijske mjere kako bi izbjegle trudnoću tijekom terapije tikagrelorom.
English: The concomitant use of ticagrelor with doses of simvastatin or lovastatin greater than 40 mg is not recommended.
Croatian: Istodobna primjena tikagrelora s dozama simvastatina ili lovastatina većima od 40 mg se ne preporučuje.
English: Co-administration of ticagrelor and levonorgestrel and ethinyl estradiol increased ethinyl estradiol exposure approximately 20% but did not alter the pharmacokinetics of levonorgestrel.
Croatian: Istodobna primjena tikagrelora i levonorgestrela i etinilestradiola je povećala izloženost etinilestradiolu za približno 20%, ali nije promijenila farmakokinetiku levonorgestrela.
English: Switching from clopidogrel 75 mg to ticagrelor 90 mg twice daily results in an absolute IPA increase of 26.4% and switching from ticagrelor to clopidogrel results in an absolute IPA decrease of 24.5%.
Croatian: Prebacivanje s klopidogrela od 75 mg na tikagrelor od 90 mg dvaput dnevno rezultira apsolutnim povećanjem IPA od 26,4% i prebacivanje s tikagrelora na klopidogrel rezultira apsolutnim smanjenjem IPA od 24,5%.
English: • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.8).
Croatian: • Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1 (vidjeti dio 4.8).
English: If a CABG procedure is planned, ticagrelor bleeding risk is increased compared to clopidogrel when discontinued within less than 96 hours prior to procedure.
Croatian: Ako se planira ugradnja aortokoronarne premosnice, povećan je rizik od krvarenja zbog tikagrelora u odnosu na klopidogrel ako se prestane s uzimanjem u roku kraćem od 96 sati prije postupka.
English: Thus, the carcinogenicity findings are considered unlikely to be relevant for humans.
Croatian: Stoga se nalazi karcinogenosti ne smatraju značajnima za ljude.
English: Fertility Ticagrelor had no effect on male or female fertility in animals (see section 5.3).
Croatian: Plodnost Tikagrelor nije imao učinak na mušku ili žensku plodnost u životinja (vidjeti dio 5.3).
English: Table 1 - Adverse reactions by frequency and system organ class (SOC)
Croatian: Tablica 1 - nuspojave prema učestalosti i klasifikaciji organskog sustava (SOC)
English: CYP2C19 and ABCB1 genotyping of 10,285 patients in PLATO provided associations of genotype groups with PLATO outcomes.
Croatian: Genotipizacija CYP2C19 i ABCB1 kod 10 285 bolesnika u studiji PLATO je dala povezanost genotipskih skupina s ishodima studije PLATO.
English: Patients taking Brilique should also take a daily low maintenance dose of ASA 75-150 mg, unless specifically contraindicated.
Croatian: Bolesnici koji uzimaju Brilique trebaju također svakodnevno uzimati i acetilsalicilatnu kiselinu u niskoj dozi održavanja od 75 - 150 mg, osim ako nije kontraindicirana.
English: CABG-related bleeding:
Croatian: Krvarenje povezano s CABG:
English: The result appeared early (absolute risk reduction [ARR] 0.6% and relative risk reduction [RRR] of 12% at 30 days), with a constant treatment effect over the entire 12-month period, yielding ARR 1.9% per year with RRR of 16%.
Croatian: Rezultati su se rano pojavili (smanjenje apsolutnog rizika - absolute risk reduction [ARR] 0,6% i smanjenje relativnog rizika - Relative Risk Reduction [RRR] od 12% nakon 30 dana), s trajnim učinkom liječenja tijekom cijelog razdoblja od 12 mjeseci, rezultirajući smanjenjem apsolutnog rizika (ARR) od 1,9% godišnje i relativnog rizika (RRR) od 16%.
English: Ticagrelor does not prevent ADP binding but when bound to the P2Y12 receptor prevents ADP-induced signal transduction.
Croatian: Tikagrelor ne sprječava vezanje ADP-a, ali kada je vezan na P2Y12 receptore sprječava prijenos signala izazvan ADP-om.